BNP PARIBAS FINANCIAL MARKETS - CORBUS PHARMACEUTICALS HLDGS ownership

CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 114 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q1 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of CORBUS PHARMACEUTICALS HLDGS
ValueSharesWeighting
Q4 2022$11
-99.9%
1000.0%0.00%
Q3 2022$16,000
-36.0%
1000.0%0.00%
Q2 2022$25,000
-52.8%
1000.0%0.00%
Q1 2022$53,000
-72.3%
100
-67.8%
0.00%
Q4 2021$191,000
-94.2%
311
-90.4%
0.00%
Q3 2021$3,292,000
-51.2%
3,227
-12.4%
0.00%
Q2 2021$6,744,000
-67.3%
3,685
-64.8%
0.00%
Q1 2021$20,628,000
-77.0%
10,471
-85.4%
0.00%
Q4 2020$89,569,000
+154.4%
71,655
+266.3%
0.00%
Q3 2020$35,212,000
-41.1%
19,562
+174.4%
0.00%
Q2 2020$59,812,000
-40.2%
7,129
-62.6%
0.00%
Q1 2020$99,984,000
+155.9%
19,081
+166.6%
0.00%
Q4 2019$39,077,000
-13.0%
7,157
-22.4%
0.00%
Q3 2019$44,892,000
+3.1%
9,218
+46.8%
0.00%
Q2 2019$43,527,000
-46.4%
6,281
-46.2%
0.00%
Q1 2019$81,183,000
+87193.5%
11,681
+72906.2%
0.00%
Q4 2018$93,000
-99.2%
16
-98.9%
0.00%
Q3 2018$11,174,000
+49.5%
1,4800.0%0.00%
Q2 2018$7,474,000
-88.2%
1,480
-85.7%
0.00%
Q1 2018$63,330,000
-18.9%
10,382
-5.7%
0.00%
Q4 2017$78,128,000
+152.8%
11,004
+154.6%
0.00%
Q3 2017$30,902,000
+5.7%
4,322
-6.9%
0.00%
Q2 2017$29,245,0004,6420.00%
Other shareholders
CORBUS PHARMACEUTICALS HLDGS shareholders Q1 2020
NameSharesValueWeighting ↓
Knoll Capital Management, LLC 5,045,870$42,335,00024.44%
MANGROVE PARTNERS IM, LLC 552,200$4,633,0001.13%
ETF MANAGERS GROUP, LLC 3,707,912$31,109,0001.10%
Ikarian Capital, LLC 1,350,000$11,327,0000.90%
GENERAL AMERICAN INVESTORS CO INC 712,400$5,977,0000.76%
AdvisorShares Investments LLC 189,814$1,593,0000.68%
Ikarian Capital, LLC 1,000,000$8,390,0000.67%
Granite Point Capital Management, L.P. 1,123,600$9,427,0000.48%
Carmignac Gestion 3,773,440$31,659,0000.44%
Omnia Family Wealth, LLC 32,356$271,467,0000.27%
View complete list of CORBUS PHARMACEUTICALS HLDGS shareholders